Ever-Growing USA on MSN8h
[New Insight] iGenics Vision Formula: Expert Analysis and Startling Consumer Complaints
Maintaining good eyesight is more critical than ever in today's fast-paced world. With rising screen time and environmental ...
Pharmabiz17h
Astellas Pharma announces US FDA confirms Class 1 resubmission of the sNDA for Izervay for geographic atrophy
Astellas Pharma announces US FDA confirms Class 1 resubmission of the sNDA for Izervay for geographic atrophy: Tokyo Saturday, January 11, 2025, 10:00 Hrs [IST] Astellas Pharma In ...
4D Molecular downgraded to Market Perform from Outperform at BMO Capital
BMO Capital downgraded 4D Molecular (FDMT) to Market Perform from Outperform with a price target of $15, down from $40. 4D-150 durability in ...
Santé log1d
InflammX Therapeutics Announces Option Agreement with Bausch + Lomb
Under the terms of the option agreement, which was signed in December 2024, Bausch + Lomb has secured the exclusive option to acquire InflammX Therapeutics during an agreed-upon option period based on ...